Companion Animal Diagnostic Market by Product (Consumable, Instrument), Technology (Immunodiagnostic, ELISA, PCR Test, Urinalysis, Hematology), Animal Type (Dog, Cat), Application (Clinical Pathology, Virology), End User - Global Forecast to 2031
The companion animal diagnostics market is expected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, at a CAGR of 8.7%. This growth is driven by several key factors shaping the future of diagnostic technology, preventive care, and precision veterinary medicine.
A key catalyst is the growing need for sophisticated diagnostic platforms as veterinary healthcare organizations seek to improve the accuracy, speed, and efficiency of current diagnostic processes. With the increasing need for a targeted, data-focused approach in companion animal healthcare, demand for high-quality diagnostic platforms is rising. Moreover, the need to shift focus to preventive healthcare and targeted disease management is being fueled by the growing demand for innovative diagnostic platforms. This trend is being augmented by AI-driven data analysis and cloud services, resulting in demand for innovative GMP-compliant diagnostic platforms.
Furthermore, the increasing incidence of chronic, infectious, and age-related diseases in domesticated pets is fueling the need for rapid, efficient diagnostic options. Veterinarians and veterinary labs are increasingly seeking support from specialty diagnostic companies to meet the ever-rising volume of cases through high-throughput testing, molecular testing, and imaging capabilities. The growing momentum toward modernizing the field of vet care, driven by real-time monitoring tools, artificial intelligence-powered predictive analytics, and cloud-based systems, is also fueling the need for new, high-quality diagnostic services.
Advances in technology, including automated analyzers, point-of-care testing, and AI interpretation, are fueling the market by improving test accuracy and turnaround times and expanding testing available in the companion animal space. With more of the companion animal diagnostics space outsourcing expertise in complex animal diagnoses or animal research, these advances also support the continued evolution of the companion animal diagnostics market.
“By technology, molecular diagnostics segment to register the highest CAGR during forecast period.”
The molecular diagnostics segment is expected to see the highest growth in the companion animal diagnostics market due to its ability to deliver accurate results for infectious diseases, genetic disorders, and cancers in pet animals. Improvements in PCR, next-generation sequencing, and liquid biopsy have increased the use of molecular diagnostics, enabling veterinarians to easily test their patients for complex ailments that were previously hard to identify. Additionally, there is a growing need for precision medicine, which requires precise diagnostic methods to provide tailored treatment plans for pets.
“By product, consumables segment accounted for larger market share in 2025.”
In 2025, the consumables segment dominated the companion animal diagnostics market, as reagents, test kits, and diagnostic strips are indispensable components of most tests performed in veterinary labs and animal health centers. Those consumables are used in everyday tests conducted for companion animals, including blood and urinalysis tests. Point-of-care and in-house testing are also widely adopted in the companion animal industry, and these consumables are used on a day-to-day basis. Furthermore, as the need to test animals increases and vet practices move toward preventive testing, there will be a growing demand for consumables, thereby maintaining their dominant market position.
“Asia Pacific to witness highest growth rate during forecast period.”
The Asia Pacific region is expected to witness the fastest growth in the companion animal diagnostics market during the forecast period, driven by the growing number of pet lovers who are spending heavily on their pets. With greater awareness of animal health and higher spending capacity among pet owners, the Asia Pacific market is growing rapidly. The increased use of advanced animal diagnostic equipment, such as point-of-care testing and molecular diagnostics, is meeting the need for high-quality diagnostics at affordable prices. Moreover, advances in animal healthcare infrastructure and animal insurance coverage are driving the animal diagnostics market in the Asia Pacific region.
Breakdown of supply-side primary interviews:
The market study covers the companion animal diagnostics market in various segments. It aims to estimate the market size and growth potential by product, technology, application, animal type, end user, and region. The study also includes an in-depth competitive analysis of the market's key players, along with their company profiles, key observations on their products and business offerings, recent developments, and key market strategies.
Reasons to Buy Report
The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger share of the market. Firms that acquire the report can implement one or more of the five strategies outlined below.
This report provides insights into the following points:
A key catalyst is the growing need for sophisticated diagnostic platforms as veterinary healthcare organizations seek to improve the accuracy, speed, and efficiency of current diagnostic processes. With the increasing need for a targeted, data-focused approach in companion animal healthcare, demand for high-quality diagnostic platforms is rising. Moreover, the need to shift focus to preventive healthcare and targeted disease management is being fueled by the growing demand for innovative diagnostic platforms. This trend is being augmented by AI-driven data analysis and cloud services, resulting in demand for innovative GMP-compliant diagnostic platforms.
Furthermore, the increasing incidence of chronic, infectious, and age-related diseases in domesticated pets is fueling the need for rapid, efficient diagnostic options. Veterinarians and veterinary labs are increasingly seeking support from specialty diagnostic companies to meet the ever-rising volume of cases through high-throughput testing, molecular testing, and imaging capabilities. The growing momentum toward modernizing the field of vet care, driven by real-time monitoring tools, artificial intelligence-powered predictive analytics, and cloud-based systems, is also fueling the need for new, high-quality diagnostic services.
Advances in technology, including automated analyzers, point-of-care testing, and AI interpretation, are fueling the market by improving test accuracy and turnaround times and expanding testing available in the companion animal space. With more of the companion animal diagnostics space outsourcing expertise in complex animal diagnoses or animal research, these advances also support the continued evolution of the companion animal diagnostics market.
“By technology, molecular diagnostics segment to register the highest CAGR during forecast period.”
The molecular diagnostics segment is expected to see the highest growth in the companion animal diagnostics market due to its ability to deliver accurate results for infectious diseases, genetic disorders, and cancers in pet animals. Improvements in PCR, next-generation sequencing, and liquid biopsy have increased the use of molecular diagnostics, enabling veterinarians to easily test their patients for complex ailments that were previously hard to identify. Additionally, there is a growing need for precision medicine, which requires precise diagnostic methods to provide tailored treatment plans for pets.
“By product, consumables segment accounted for larger market share in 2025.”
In 2025, the consumables segment dominated the companion animal diagnostics market, as reagents, test kits, and diagnostic strips are indispensable components of most tests performed in veterinary labs and animal health centers. Those consumables are used in everyday tests conducted for companion animals, including blood and urinalysis tests. Point-of-care and in-house testing are also widely adopted in the companion animal industry, and these consumables are used on a day-to-day basis. Furthermore, as the need to test animals increases and vet practices move toward preventive testing, there will be a growing demand for consumables, thereby maintaining their dominant market position.
“Asia Pacific to witness highest growth rate during forecast period.”
The Asia Pacific region is expected to witness the fastest growth in the companion animal diagnostics market during the forecast period, driven by the growing number of pet lovers who are spending heavily on their pets. With greater awareness of animal health and higher spending capacity among pet owners, the Asia Pacific market is growing rapidly. The increased use of advanced animal diagnostic equipment, such as point-of-care testing and molecular diagnostics, is meeting the need for high-quality diagnostics at affordable prices. Moreover, advances in animal healthcare infrastructure and animal insurance coverage are driving the animal diagnostics market in the Asia Pacific region.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%)
- By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%)
- By Region: North America (45%), Europe (15%), Asia Pacific (25%), Latin America (10%), and the Middle East & Africa (5%)
- By End User: Diagnostic Laboratories (45%), Veterinary Hospitals & Clinics (30%), Veterinary Research Institutes & Universities (15%), and Home Care Settings (10%)
- By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)
The market study covers the companion animal diagnostics market in various segments. It aims to estimate the market size and growth potential by product, technology, application, animal type, end user, and region. The study also includes an in-depth competitive analysis of the market's key players, along with their company profiles, key observations on their products and business offerings, recent developments, and key market strategies.
Reasons to Buy Report
The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger share of the market. Firms that acquire the report can implement one or more of the five strategies outlined below.
This report provides insights into the following points:
- Analysis of key drivers (growth in the companion animal population, rising demand for pet insurance, and increased spending on animal healthcare), restraints (high cost of diagnostic devices, stringent regulations and lengthy approval processes for diagnostic products), opportunities (growing demand for rapid tests and portable instruments for POC diagnostics, integration of AI and ML for enhanced disease diagnosis), and challenges (shortage of veterinary practitioners in emerging markets, barriers to adoption in small clinics) influencing the growth of the companion animal diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the companion animal diagnostics market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of companion animal diagnostic products across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the companion animal diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the companion animal diagnostics market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.5 UNITS CONSIDERED
1.4 MARKET STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN COMPANION ANIMAL DIAGNOSTICS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 COMPANION ANIMAL DIAGNOSTICS MARKET OVERVIEW
3.2 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2025)
3.3 COMPANION ANIMAL DIAGNOSTICS MARKET: REGIONAL MIX
3.4 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.5 COMPANION ANIMAL DIAGNOSTICS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growth in companion animal population
4.2.1.2 Increasing demand for pet insurance and growth in animal healthcare expenditure
4.2.1.3 Growing number of veterinary practitioners
4.2.1.4 Increasing prevalence of infectious, parasitic, and chronic diseases in pets
4.2.2 RESTRAINTS
4.2.2.1 Rising pet care costs
4.2.2.2 Limited access to advanced veterinary diagnostic services in developing regions
4.2.3 OPPORTUNITIES
4.2.3.1 Growing demand for rapid tests and portable instruments for POC diagnostics
4.2.3.2 Utilization of AI and ML for enhanced disease diagnosis
4.2.4 CHALLENGES
4.2.4.1 Low awareness regarding preventive diagnostics among pet owners in price-sensitive markets
4.2.4.2 Regulatory and reimbursement limitations in veterinary healthcare diagnostics
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN COMPANION ANIMAL DIAGNOSTICS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
5.5.2.1 Average selling price trend of rapid test kits, by region, 2023?2025
5.5.2.2 Average selling price trend of ELISA/immunodiagnostic test kits & reagents, by region, 2023?2025
5.5.2.3 Average selling price trend of clinical chemistry reagents, clips & cartridges, by region, 2023?2025
5.5.2.4 Average selling price trend of blood glucose strips, by region, 2023?2025
5.5.2.5 Average selling price trend of hematology analyzers, by region, 2023?2025
5.6 TRADE ANALYSIS
5.6.1 TRADE DATA FOR HS CODE 9018
5.6.1.1 Import data for HS Code 9018
5.6.1.2 Export data for HS Code 9018
5.6.2 TRADE DATA FOR HS CODE 3822
5.6.2.1 Import data for HS Code 3822
5.6.2.2 Export data for HS Code 3822
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING SCENARIO
5.10 SUCCESS STORIES & REAL-WORLD APPLICATIONS
5.10.1 NGS-BASED LIQUID BIOPSY FOR CANINE CANCER DETECTION
5.10.2 ADOPTION OF AI-ENABLED POC DIAGNOSTIC PLATFORM FOR PARASITE DETECTION
5.10.3 DEVELOPMENT OF SNAP 4DX PLUS TEST FOR RAPID VECTOR-BORNE DISEASE DETECTION
5.11 IMPACT OF US TARIFFS—COMPANION ANIMAL DIAGNOSTICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRIES/REGIONS
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Veterinary Hospitals & Clinics
5.11.5.2 Veterinary Reference Laboratories
5.11.5.3 Veterinary Research Institutes & Universities
5.11.5.4 Home Care Settings
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 AI-ENABLED DIAGNOSTICS
6.1.2 PORTABLE INSTRUMENTS FOR POC DIAGNOSTIC SERVICES
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 MICROFLUIDIC DEVICES FOR VETERINARY DIAGNOSTICS
6.2.2 CRISPR-BASED MOLECULAR DIAGNOSTICS
6.3 ADJACENT TECHNOLOGIES
6.3.1 WEARABLE BIOSENSORS & REMOTE MONITORING DEVICES
6.3.2 BREATH & SALIVA-BASED DIAGNOSTIC TOOLS
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.4.1 NEAR TERM (2025–2027)
6.4.2 MID-TERM (2028–2030)
6.4.3 LONG TERM (2030+)
6.5 PATENT ANALYSIS
6.5.1 PATENT PUBLICATION TRENDS FOR COMPANION ANIMAL DIAGNOSTIC KITS
6.5.2 JURISDICTION & TOP APPLICANT ANALYSIS
6.6 FUTURE APPLICATIONS
6.6.1 AI-DRIVEN PREDICTIVE DIAGNOSTICS
6.6.2 FULLY INTEGRATED DIGITAL VETERINARY ECOSYSTEMS
6.6.3 PRECISION & PERSONALIZED VETERINARY DIAGNOSTICS
6.6.4 REMOTE & HOME-BASED PET HEALTH MONITORING
6.6.5 AUTOMATED HIGH-THROUGHPUT VETERINARY LABORATORIES
6.7 IMPACT OF AI/GENERATIVE AI ON COMPANION ANIMAL DIAGNOSTICS MARKET
6.7.1 INTRODUCTION
6.7.2 MARKET POTENTIAL IN COMPANION ANIMAL DIAGNOSTIC ECOSYSTEM
6.7.3 AI USE CASES
6.7.4 KEY COMPANIES IMPLEMENTING AI IN COMPANION ANIMAL DIAGNOSTICS MARKET
7 REGULATORY LANDSCAPE & SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.1.1 North America
7.1.1.2 Europe
7.1.1.3 Rest of the world
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR COMPANION ANIMAL DIAGNOSTIC PRODUCTS
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 KEY STAKEHOLDERS & BUYING CRITERIA
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.1.2 BUYING CRITERIA
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1 DECISION-MAKING PROCESS
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4 MARKET PROFITABILITY
9 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 CONSUMABLES
9.2.1 RECURRING NATURE TO BOOST DEMAND
9.3 INSTRUMENTS
9.3.1 INCREASING DEMAND FOR POC ANALYZERS TO DRIVE MARKET
10 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 IMMUNODIAGNOSTICS
10.2.1 LATERAL FLOW ASSAYS
10.2.1.1 Rapid tests
10.2.1.1.1 Growing prevalence of infectious diseases in pets to fuel demand
10.2.1.1.2 Global volume analysis of rapid tests, 2024–2031 (thousand units)
10.2.1.2 Strip readers
10.2.1.2.1 Advancements in digital and AI-enabled diagnostics to support adoption
10.2.1.2.2 Global volume analysis of strip readers, 2024–2031 (thousand units)
10.2.2 ELISA TESTS
10.2.2.1 Higher sensitivity and specificity of ELISA testing to support market expansion
10.2.3 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS
10.2.3.1 Rising incidence of allergies and dermatological conditions to fuel market growth
10.2.4 IMMUNOASSAY ANALYZERS
10.2.4.1 Increasing automation in veterinary diagnostics to drive market growth
10.2.5 RADIOIMMUNOASSAYS
10.2.5.1 Growing demand for sensitive hormone and endocrine testing to fuel market
10.2.6 OTHER IMMUNODIAGNOSTICS PRODUCTS
10.3 CLINICAL BIOCHEMISTRY
10.3.1 CLINICAL CHEMISTRY ANALYSIS
10.3.1.1 Clinical chemistry reagents, clips, and cartridges
10.3.1.1.1 Increasing utilization of consumable-based diagnostic workflows to fuel market
10.3.1.1.2 Global volume analysis of clinical chemistry reagents, clips, and cartridges, 2024–2031 (thousand units)
10.3.1.2 Clinical chemistry analyzers
10.3.1.2.1 Growing adoption of in-house veterinary diagnostics to drive analyzer demand
10.3.1.2.2 Global volume analysis of clinical chemistry analyzers, 2024–2031 (thousand units)
10.3.2 BLOOD GAS & ELECTROLYTE ANALYSIS
10.3.2.1 Blood gas and electrolyte reagents, clips, and cartridges
10.3.2.1.1 Rising demand for rapid point-of-care consumables to boost market
10.3.2.1.2 Global volume analysis of blood gas & electrolyte reagents, clips, and cartridges, 2024–2031 (thousand units)
10.3.2.2 Blood gas & electrolyte analyzers
10.3.2.2.1 Increasing adoption of compact critical-care analyzers in veterinary clinics to drive market
10.3.2.2.2 Global volume analysis of blood gas & electrolyte analyzers, 2024–2031 (thousand units)
10.3.3 GLUCOSE MONITORING
10.3.3.1 Blood glucose strips
10.3.3.1.1 Increasing home-based diabetes management to fuel market
10.3.3.1.2 Global volume analysis of blood glucose strips, 2024–2031 (thousand units)
10.3.3.2 Glucose monitors
10.3.3.2.1 Advancements in portable and continuous glucose monitoring technologies to drive market growth
10.3.3.2.2 Global volume analysis of glucose monitors, 2024–2031 (thousand units)
10.3.3.3 Urine glucose strips
10.3.3.3.1 Cost-effective and non-invasive diabetes screening to propel market
10.3.3.3.2 Global volume analysis of urine glucose strips, 2024–2031 (thousand units)
10.4 MOLECULAR DIAGNOSTICS
10.4.1 PCR TESTS
10.4.1.1 Increasing prevalence of infectious diseases in companion animals to support growth
10.4.2 MICROARRAYS
10.4.2.1 Growing focus on genomic profiling and multiplex testing to drive market
10.4.3 NUCLEIC ACID SEQUENCING
10.4.3.1 Expanding applications of genomic analysis in veterinary medicine to drive demand
10.4.4 OTHER MOLECULAR DIAGNOSTICS PRODUCTS
10.5 URINALYSIS
10.5.1 URINALYSIS CLIPS & CARTRIDGES
10.5.1.1 Growing use of consumable-based urine testing workflows to drive growth
10.5.2 URINE ANALYZERS
10.5.2.1 Increasing automation in veterinary urinalysis testing to support market growth
10.5.3 URINE TEST STRIPS
10.5.3.1 Rising demand for rapid and cost-effective urine screening tests to drive market
10.6 HEMATOLOGY
10.6.1 HEMATOLOGY CARTRIDGES
10.6.1.1 Rising use of disposable consumables in automated hematology workflows to fuel demand
10.6.2 HEMATOLOGY ANALYZERS
10.6.2.1 Growing demand for rapid complete blood count testing to support market growth
10.7 OTHER TECHNOLOGIES
11 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 CLINICAL PATHOLOGY
11.2.1 INCREASING PREVENTIVE HEALTH SCREENING AND CHRONIC DISEASE MONITORING DRIVES DEMAND
11.3 BACTERIOLOGY
11.3.1 RISING BACTERIAL INFECTIONS AND ANTIMICROBIAL RESISTANCE CONCERNS BOOST MARKET GROWTH
11.4 VIROLOGY
11.4.1 GROWING PREVALENCE OF COMPANION ANIMAL VIRAL DISEASES DRIVES GROWTH
11.5 PARASITOLOGY
11.5.1 INCREASING PARASITIC AND VECTOR-BORNE DISEASE BURDEN SUPPORTS DIAGNOSTIC ADOPTION
11.6 OTHER APPLICATIONS
12 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE
12.1 INTRODUCTION
12.2 DOGS
12.2.1 RISING PREVALENCE OF CANINE CHRONIC AND VECTOR-BORNE DISEASES DRIVES DIAGNOSTIC DEMAND
12.3 CATS
12.3.1 GROWING AWARENESS OF FELINE INFECTIOUS AND KIDNEY DISEASES BOOSTS MARKET GROWTH
12.4 HORSE
12.4.1 INCREASING EQUINE HEALTH MONITORING SUPPORTS DIAGNOSTIC ADOPTION
12.5 OTHER COMPANION ANIMALS
13 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER
13.1 INTRODUCTION
13.2 VETERINARY HOSPITALS & CLINICS
13.2.1 EXPANDING ADOPTION OF IN-HOUSE POINT-OF-CARE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET
13.3 VETERINARY REFERENCE LABORATORIES
13.3.1 RISING DEMAND FOR SPECIALIZED AND HIGH-COMPLEXITY VETERINARY DIAGNOSTIC TESTING TO PROPEL MARKET
13.4 VETERINARY RESEARCH INSTITUTES & UNIVERSITIES
13.4.1 INCREASING RESEARCH FOCUS ON PRECISION AND MOLECULAR VETERINARY DIAGNOSTICS TO SUPPORT GROWTH
13.5 HOME CARE SETTINGS
13.5.1 GROWING ADOPTION OF AT-HOME PET HEALTH MONITORING AND DIAGNOSTIC TECHNOLOGIES TO BOOST DEMAND
14 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.2.3 US
14.2.3.1 Rising preventive pet healthcare spending to drive market
14.2.4 CANADA
14.2.4.1 Increasing veterinary visits and growing pet population to drive market
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2 EUROPE: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.3.3 GERMANY
14.3.3.1 Large companion animal population and premium veterinary care fuel market growth
14.3.4 UK
14.3.4.1 High veterinary expenditure and rising chronic pet diseases support diagnostics demand
14.3.5 FRANCE
14.3.5.1 Willingness of pet owners to spend on pet health to drive market
14.3.6 ITALY
14.3.6.1 Expansion of veterinary services supports market growth
14.3.7 SPAIN
14.3.7.1 Growing pet care economy and animal welfare initiatives to fuel market
14.3.8 NETHERLANDS
14.3.8.1 Developments in veterinary diagnostic products to support market growth
14.3.9 SWEDEN
14.3.9.1 Growing companion animal care and advanced veterinary infrastructure supporting market growth
14.3.10 POLAND
14.3.10.1 Expanding veterinary infrastructure and rising pet ownership support market development
14.3.11 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.4.3 CHINA
14.4.3.1 Growing urban pet population and rising adoption of pet insurance to propel market
14.4.4 JAPAN
14.4.4.1 Aging pet population and premium veterinary care to support market growth
14.4.5 INDIA
14.4.5.1 Expanding pet care industry and rising preventive healthcare awareness fuel market growth
14.4.6 AUSTRALIA
14.4.6.1 High veterinary expenditure and strong pet insurance penetration to support market growth
14.4.7 SOUTH KOREA
14.4.7.1 Digital veterinary healthcare expansion to drive market
14.4.8 THAILAND
14.4.8.1 Urban pet adoption and improving veterinary infrastructure to drive market
14.4.9 NEW ZEALAND
14.4.9.1 Strong animal welfare culture and preventive care trends support market expansion
14.4.10 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 LATIN AMERICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.5.3 BRAZIL
14.5.3.1 Massive companion animal population to boost demand
14.5.4 MEXICO
14.5.4.1 High pet ownership and expanding veterinary services to support market growth
14.5.5 ARGENTINA
14.5.5.1 Strong pet humanization and preventive healthcare trends support market growth
14.5.6 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.6.3 GCC COUNTRIES
14.6.3.1 Kingdom of Saudi Arabia (KSA)
14.6.3.1.1 Government initiatives to drive market growth
14.6.3.2 United Arab Emirates (UAE)
14.6.3.2.1 Premium veterinary services and rising pet ownership to drive market
14.6.3.3 Rest of GCC Countries
14.6.4 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.3 REVENUE ANALYSIS, 2021?2025
15.4 MARKET SHARE ANALYSIS, 2025
15.4.1 RANKING OF KEY MARKET PLAYERS
15.4.2 US MARKET SHARE ANALYSIS, 2025
15.4.3 EUROPE MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Product footprint
15.5.5.4 Technology footprint
15.5.5.5 Animal type footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups
15.7 BRAND/PRODUCT COMPARISON
15.8 R&D EXPENDITURE OF KEY PLAYERS
15.9 COMPANY VALUATION & FINANCIAL METRICS
15.9.1 FINANCIAL METRICS
15.9.2 COMPANY VALUATION
15.10 COMPETITIVE SCENARIO
15.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
15.10.2 DEALS
15.10.3 EXPANSIONS
15.10.4 OTHER DEVELOPMENTS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 IDEXX LABORATORIES, INC.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & enhancements
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 ANTECH DIAGNOSTICS, INC.
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Expansions
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 ZOETIS SERVICES LLC
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches & enhancements
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.3.4 Other developments
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 FUJIFILM CORPORATION
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 MnM view
16.1.4.3.1 Key strengths
16.1.4.3.2 Strategic choices
16.1.4.3.3 Weaknesses & competitive threats
16.1.5 THERMO FISHER SCIENTIFIC INC.
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 MnM view
16.1.5.3.1 Key strengths
16.1.5.3.2 Strategic choices
16.1.5.3.3 Weaknesses & competitive threats
16.1.6 BIOM?RIEUX
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches & approvals
16.1.7 BIONOTE
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches & enhancements
16.1.7.3.2 Deals
16.1.8 VIRBAC
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.8.3.2 Expansions
16.1.9 RANDOX LABORATORIES LTD.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Deals
16.1.9.3.2 Expansions
16.1.10 INDICAL BIOSCIENCE GMBH
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product enhancements
16.1.11 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches
16.1.11.3.2 Expansions
16.1.12 BOULE
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches
16.1.12.3.2 Deals
16.1.13 INNOVATIVE DIAGNOSTICS
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Other developments
16.1.14 MEGACOR DIAGNOSTIK GMBH
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches & enhancements
16.1.15 BIOGAL
16.1.15.1 Business overview
16.1.15.2 Products offered
16.2 OTHER PLAYERS
16.2.1 GOLD STANDARD DIAGNOSTICS
16.2.2 AGROLABO S.P.A.
16.2.3 PRECISION BIOSENSOR, INC.
16.2.4 SKYLA CORPORATION
16.2.5 FASSISI, GMBH
16.2.6 WOODLEY EQUIPMENT COMPANY LTD
16.2.7 BIOPANDA REAGENTS LTD
16.2.8 SKYER, INC.
16.2.9 RING BIOTECHNOLOGY CO., LTD.
16.2.10 SHENZHEN BIOEASY BIOTECHNOLOGY, INC.
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.2 RESEARCH METHODOLOGY DESIGN
17.2.1 SECONDARY DATA
17.2.1.1 Key data from secondary sources
17.2.2 PRIMARY DATA
17.2.2.1 Key data from primary sources
17.2.2.2 Key industry insights
17.3 MARKET SIZE ESTIMATION
17.3.1 BOTTOM-UP APPROACH
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 MARKET SHARE ANALYSIS
17.5.1 RESEARCH ASSUMPTIONS
17.5.2 GROWTH RATE ASSUMPTIONS
17.6 RISK ASSESSMENT
17.7 RESEARCH LIMITATIONS
17.7.1 METHODOLOGY-RELATED LIMITATIONS
17.7.2 SCOPE-RELATED LIMITATIONS
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.3.1 PRODUCT ANALYSIS
18.3.2 COMPANY INFORMATION
18.3.3 GEOGRAPHIC ANALYSIS
18.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
18.3.5 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT
18.3.6 BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
18.3.7 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.5 UNITS CONSIDERED
1.4 MARKET STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN COMPANION ANIMAL DIAGNOSTICS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 COMPANION ANIMAL DIAGNOSTICS MARKET OVERVIEW
3.2 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2025)
3.3 COMPANION ANIMAL DIAGNOSTICS MARKET: REGIONAL MIX
3.4 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.5 COMPANION ANIMAL DIAGNOSTICS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growth in companion animal population
4.2.1.2 Increasing demand for pet insurance and growth in animal healthcare expenditure
4.2.1.3 Growing number of veterinary practitioners
4.2.1.4 Increasing prevalence of infectious, parasitic, and chronic diseases in pets
4.2.2 RESTRAINTS
4.2.2.1 Rising pet care costs
4.2.2.2 Limited access to advanced veterinary diagnostic services in developing regions
4.2.3 OPPORTUNITIES
4.2.3.1 Growing demand for rapid tests and portable instruments for POC diagnostics
4.2.3.2 Utilization of AI and ML for enhanced disease diagnosis
4.2.4 CHALLENGES
4.2.4.1 Low awareness regarding preventive diagnostics among pet owners in price-sensitive markets
4.2.4.2 Regulatory and reimbursement limitations in veterinary healthcare diagnostics
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN COMPANION ANIMAL DIAGNOSTICS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
5.5.2.1 Average selling price trend of rapid test kits, by region, 2023?2025
5.5.2.2 Average selling price trend of ELISA/immunodiagnostic test kits & reagents, by region, 2023?2025
5.5.2.3 Average selling price trend of clinical chemistry reagents, clips & cartridges, by region, 2023?2025
5.5.2.4 Average selling price trend of blood glucose strips, by region, 2023?2025
5.5.2.5 Average selling price trend of hematology analyzers, by region, 2023?2025
5.6 TRADE ANALYSIS
5.6.1 TRADE DATA FOR HS CODE 9018
5.6.1.1 Import data for HS Code 9018
5.6.1.2 Export data for HS Code 9018
5.6.2 TRADE DATA FOR HS CODE 3822
5.6.2.1 Import data for HS Code 3822
5.6.2.2 Export data for HS Code 3822
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING SCENARIO
5.10 SUCCESS STORIES & REAL-WORLD APPLICATIONS
5.10.1 NGS-BASED LIQUID BIOPSY FOR CANINE CANCER DETECTION
5.10.2 ADOPTION OF AI-ENABLED POC DIAGNOSTIC PLATFORM FOR PARASITE DETECTION
5.10.3 DEVELOPMENT OF SNAP 4DX PLUS TEST FOR RAPID VECTOR-BORNE DISEASE DETECTION
5.11 IMPACT OF US TARIFFS—COMPANION ANIMAL DIAGNOSTICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRIES/REGIONS
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Veterinary Hospitals & Clinics
5.11.5.2 Veterinary Reference Laboratories
5.11.5.3 Veterinary Research Institutes & Universities
5.11.5.4 Home Care Settings
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 AI-ENABLED DIAGNOSTICS
6.1.2 PORTABLE INSTRUMENTS FOR POC DIAGNOSTIC SERVICES
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 MICROFLUIDIC DEVICES FOR VETERINARY DIAGNOSTICS
6.2.2 CRISPR-BASED MOLECULAR DIAGNOSTICS
6.3 ADJACENT TECHNOLOGIES
6.3.1 WEARABLE BIOSENSORS & REMOTE MONITORING DEVICES
6.3.2 BREATH & SALIVA-BASED DIAGNOSTIC TOOLS
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.4.1 NEAR TERM (2025–2027)
6.4.2 MID-TERM (2028–2030)
6.4.3 LONG TERM (2030+)
6.5 PATENT ANALYSIS
6.5.1 PATENT PUBLICATION TRENDS FOR COMPANION ANIMAL DIAGNOSTIC KITS
6.5.2 JURISDICTION & TOP APPLICANT ANALYSIS
6.6 FUTURE APPLICATIONS
6.6.1 AI-DRIVEN PREDICTIVE DIAGNOSTICS
6.6.2 FULLY INTEGRATED DIGITAL VETERINARY ECOSYSTEMS
6.6.3 PRECISION & PERSONALIZED VETERINARY DIAGNOSTICS
6.6.4 REMOTE & HOME-BASED PET HEALTH MONITORING
6.6.5 AUTOMATED HIGH-THROUGHPUT VETERINARY LABORATORIES
6.7 IMPACT OF AI/GENERATIVE AI ON COMPANION ANIMAL DIAGNOSTICS MARKET
6.7.1 INTRODUCTION
6.7.2 MARKET POTENTIAL IN COMPANION ANIMAL DIAGNOSTIC ECOSYSTEM
6.7.3 AI USE CASES
6.7.4 KEY COMPANIES IMPLEMENTING AI IN COMPANION ANIMAL DIAGNOSTICS MARKET
7 REGULATORY LANDSCAPE & SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.1.1 North America
7.1.1.2 Europe
7.1.1.3 Rest of the world
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR COMPANION ANIMAL DIAGNOSTIC PRODUCTS
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 KEY STAKEHOLDERS & BUYING CRITERIA
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.1.2 BUYING CRITERIA
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1 DECISION-MAKING PROCESS
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4 MARKET PROFITABILITY
9 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 CONSUMABLES
9.2.1 RECURRING NATURE TO BOOST DEMAND
9.3 INSTRUMENTS
9.3.1 INCREASING DEMAND FOR POC ANALYZERS TO DRIVE MARKET
10 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 IMMUNODIAGNOSTICS
10.2.1 LATERAL FLOW ASSAYS
10.2.1.1 Rapid tests
10.2.1.1.1 Growing prevalence of infectious diseases in pets to fuel demand
10.2.1.1.2 Global volume analysis of rapid tests, 2024–2031 (thousand units)
10.2.1.2 Strip readers
10.2.1.2.1 Advancements in digital and AI-enabled diagnostics to support adoption
10.2.1.2.2 Global volume analysis of strip readers, 2024–2031 (thousand units)
10.2.2 ELISA TESTS
10.2.2.1 Higher sensitivity and specificity of ELISA testing to support market expansion
10.2.3 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS
10.2.3.1 Rising incidence of allergies and dermatological conditions to fuel market growth
10.2.4 IMMUNOASSAY ANALYZERS
10.2.4.1 Increasing automation in veterinary diagnostics to drive market growth
10.2.5 RADIOIMMUNOASSAYS
10.2.5.1 Growing demand for sensitive hormone and endocrine testing to fuel market
10.2.6 OTHER IMMUNODIAGNOSTICS PRODUCTS
10.3 CLINICAL BIOCHEMISTRY
10.3.1 CLINICAL CHEMISTRY ANALYSIS
10.3.1.1 Clinical chemistry reagents, clips, and cartridges
10.3.1.1.1 Increasing utilization of consumable-based diagnostic workflows to fuel market
10.3.1.1.2 Global volume analysis of clinical chemistry reagents, clips, and cartridges, 2024–2031 (thousand units)
10.3.1.2 Clinical chemistry analyzers
10.3.1.2.1 Growing adoption of in-house veterinary diagnostics to drive analyzer demand
10.3.1.2.2 Global volume analysis of clinical chemistry analyzers, 2024–2031 (thousand units)
10.3.2 BLOOD GAS & ELECTROLYTE ANALYSIS
10.3.2.1 Blood gas and electrolyte reagents, clips, and cartridges
10.3.2.1.1 Rising demand for rapid point-of-care consumables to boost market
10.3.2.1.2 Global volume analysis of blood gas & electrolyte reagents, clips, and cartridges, 2024–2031 (thousand units)
10.3.2.2 Blood gas & electrolyte analyzers
10.3.2.2.1 Increasing adoption of compact critical-care analyzers in veterinary clinics to drive market
10.3.2.2.2 Global volume analysis of blood gas & electrolyte analyzers, 2024–2031 (thousand units)
10.3.3 GLUCOSE MONITORING
10.3.3.1 Blood glucose strips
10.3.3.1.1 Increasing home-based diabetes management to fuel market
10.3.3.1.2 Global volume analysis of blood glucose strips, 2024–2031 (thousand units)
10.3.3.2 Glucose monitors
10.3.3.2.1 Advancements in portable and continuous glucose monitoring technologies to drive market growth
10.3.3.2.2 Global volume analysis of glucose monitors, 2024–2031 (thousand units)
10.3.3.3 Urine glucose strips
10.3.3.3.1 Cost-effective and non-invasive diabetes screening to propel market
10.3.3.3.2 Global volume analysis of urine glucose strips, 2024–2031 (thousand units)
10.4 MOLECULAR DIAGNOSTICS
10.4.1 PCR TESTS
10.4.1.1 Increasing prevalence of infectious diseases in companion animals to support growth
10.4.2 MICROARRAYS
10.4.2.1 Growing focus on genomic profiling and multiplex testing to drive market
10.4.3 NUCLEIC ACID SEQUENCING
10.4.3.1 Expanding applications of genomic analysis in veterinary medicine to drive demand
10.4.4 OTHER MOLECULAR DIAGNOSTICS PRODUCTS
10.5 URINALYSIS
10.5.1 URINALYSIS CLIPS & CARTRIDGES
10.5.1.1 Growing use of consumable-based urine testing workflows to drive growth
10.5.2 URINE ANALYZERS
10.5.2.1 Increasing automation in veterinary urinalysis testing to support market growth
10.5.3 URINE TEST STRIPS
10.5.3.1 Rising demand for rapid and cost-effective urine screening tests to drive market
10.6 HEMATOLOGY
10.6.1 HEMATOLOGY CARTRIDGES
10.6.1.1 Rising use of disposable consumables in automated hematology workflows to fuel demand
10.6.2 HEMATOLOGY ANALYZERS
10.6.2.1 Growing demand for rapid complete blood count testing to support market growth
10.7 OTHER TECHNOLOGIES
11 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 CLINICAL PATHOLOGY
11.2.1 INCREASING PREVENTIVE HEALTH SCREENING AND CHRONIC DISEASE MONITORING DRIVES DEMAND
11.3 BACTERIOLOGY
11.3.1 RISING BACTERIAL INFECTIONS AND ANTIMICROBIAL RESISTANCE CONCERNS BOOST MARKET GROWTH
11.4 VIROLOGY
11.4.1 GROWING PREVALENCE OF COMPANION ANIMAL VIRAL DISEASES DRIVES GROWTH
11.5 PARASITOLOGY
11.5.1 INCREASING PARASITIC AND VECTOR-BORNE DISEASE BURDEN SUPPORTS DIAGNOSTIC ADOPTION
11.6 OTHER APPLICATIONS
12 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE
12.1 INTRODUCTION
12.2 DOGS
12.2.1 RISING PREVALENCE OF CANINE CHRONIC AND VECTOR-BORNE DISEASES DRIVES DIAGNOSTIC DEMAND
12.3 CATS
12.3.1 GROWING AWARENESS OF FELINE INFECTIOUS AND KIDNEY DISEASES BOOSTS MARKET GROWTH
12.4 HORSE
12.4.1 INCREASING EQUINE HEALTH MONITORING SUPPORTS DIAGNOSTIC ADOPTION
12.5 OTHER COMPANION ANIMALS
13 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER
13.1 INTRODUCTION
13.2 VETERINARY HOSPITALS & CLINICS
13.2.1 EXPANDING ADOPTION OF IN-HOUSE POINT-OF-CARE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET
13.3 VETERINARY REFERENCE LABORATORIES
13.3.1 RISING DEMAND FOR SPECIALIZED AND HIGH-COMPLEXITY VETERINARY DIAGNOSTIC TESTING TO PROPEL MARKET
13.4 VETERINARY RESEARCH INSTITUTES & UNIVERSITIES
13.4.1 INCREASING RESEARCH FOCUS ON PRECISION AND MOLECULAR VETERINARY DIAGNOSTICS TO SUPPORT GROWTH
13.5 HOME CARE SETTINGS
13.5.1 GROWING ADOPTION OF AT-HOME PET HEALTH MONITORING AND DIAGNOSTIC TECHNOLOGIES TO BOOST DEMAND
14 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.2.3 US
14.2.3.1 Rising preventive pet healthcare spending to drive market
14.2.4 CANADA
14.2.4.1 Increasing veterinary visits and growing pet population to drive market
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2 EUROPE: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.3.3 GERMANY
14.3.3.1 Large companion animal population and premium veterinary care fuel market growth
14.3.4 UK
14.3.4.1 High veterinary expenditure and rising chronic pet diseases support diagnostics demand
14.3.5 FRANCE
14.3.5.1 Willingness of pet owners to spend on pet health to drive market
14.3.6 ITALY
14.3.6.1 Expansion of veterinary services supports market growth
14.3.7 SPAIN
14.3.7.1 Growing pet care economy and animal welfare initiatives to fuel market
14.3.8 NETHERLANDS
14.3.8.1 Developments in veterinary diagnostic products to support market growth
14.3.9 SWEDEN
14.3.9.1 Growing companion animal care and advanced veterinary infrastructure supporting market growth
14.3.10 POLAND
14.3.10.1 Expanding veterinary infrastructure and rising pet ownership support market development
14.3.11 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.4.3 CHINA
14.4.3.1 Growing urban pet population and rising adoption of pet insurance to propel market
14.4.4 JAPAN
14.4.4.1 Aging pet population and premium veterinary care to support market growth
14.4.5 INDIA
14.4.5.1 Expanding pet care industry and rising preventive healthcare awareness fuel market growth
14.4.6 AUSTRALIA
14.4.6.1 High veterinary expenditure and strong pet insurance penetration to support market growth
14.4.7 SOUTH KOREA
14.4.7.1 Digital veterinary healthcare expansion to drive market
14.4.8 THAILAND
14.4.8.1 Urban pet adoption and improving veterinary infrastructure to drive market
14.4.9 NEW ZEALAND
14.4.9.1 Strong animal welfare culture and preventive care trends support market expansion
14.4.10 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 LATIN AMERICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.5.3 BRAZIL
14.5.3.1 Massive companion animal population to boost demand
14.5.4 MEXICO
14.5.4.1 High pet ownership and expanding veterinary services to support market growth
14.5.5 ARGENTINA
14.5.5.1 Strong pet humanization and preventive healthcare trends support market growth
14.5.6 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031
14.6.3 GCC COUNTRIES
14.6.3.1 Kingdom of Saudi Arabia (KSA)
14.6.3.1.1 Government initiatives to drive market growth
14.6.3.2 United Arab Emirates (UAE)
14.6.3.2.1 Premium veterinary services and rising pet ownership to drive market
14.6.3.3 Rest of GCC Countries
14.6.4 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.3 REVENUE ANALYSIS, 2021?2025
15.4 MARKET SHARE ANALYSIS, 2025
15.4.1 RANKING OF KEY MARKET PLAYERS
15.4.2 US MARKET SHARE ANALYSIS, 2025
15.4.3 EUROPE MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Product footprint
15.5.5.4 Technology footprint
15.5.5.5 Animal type footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups
15.7 BRAND/PRODUCT COMPARISON
15.8 R&D EXPENDITURE OF KEY PLAYERS
15.9 COMPANY VALUATION & FINANCIAL METRICS
15.9.1 FINANCIAL METRICS
15.9.2 COMPANY VALUATION
15.10 COMPETITIVE SCENARIO
15.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
15.10.2 DEALS
15.10.3 EXPANSIONS
15.10.4 OTHER DEVELOPMENTS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 IDEXX LABORATORIES, INC.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & enhancements
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 ANTECH DIAGNOSTICS, INC.
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Expansions
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 ZOETIS SERVICES LLC
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches & enhancements
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.3.4 Other developments
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 FUJIFILM CORPORATION
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 MnM view
16.1.4.3.1 Key strengths
16.1.4.3.2 Strategic choices
16.1.4.3.3 Weaknesses & competitive threats
16.1.5 THERMO FISHER SCIENTIFIC INC.
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 MnM view
16.1.5.3.1 Key strengths
16.1.5.3.2 Strategic choices
16.1.5.3.3 Weaknesses & competitive threats
16.1.6 BIOM?RIEUX
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches & approvals
16.1.7 BIONOTE
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches & enhancements
16.1.7.3.2 Deals
16.1.8 VIRBAC
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.8.3.2 Expansions
16.1.9 RANDOX LABORATORIES LTD.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Deals
16.1.9.3.2 Expansions
16.1.10 INDICAL BIOSCIENCE GMBH
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product enhancements
16.1.11 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches
16.1.11.3.2 Expansions
16.1.12 BOULE
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches
16.1.12.3.2 Deals
16.1.13 INNOVATIVE DIAGNOSTICS
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Other developments
16.1.14 MEGACOR DIAGNOSTIK GMBH
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches & enhancements
16.1.15 BIOGAL
16.1.15.1 Business overview
16.1.15.2 Products offered
16.2 OTHER PLAYERS
16.2.1 GOLD STANDARD DIAGNOSTICS
16.2.2 AGROLABO S.P.A.
16.2.3 PRECISION BIOSENSOR, INC.
16.2.4 SKYLA CORPORATION
16.2.5 FASSISI, GMBH
16.2.6 WOODLEY EQUIPMENT COMPANY LTD
16.2.7 BIOPANDA REAGENTS LTD
16.2.8 SKYER, INC.
16.2.9 RING BIOTECHNOLOGY CO., LTD.
16.2.10 SHENZHEN BIOEASY BIOTECHNOLOGY, INC.
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.2 RESEARCH METHODOLOGY DESIGN
17.2.1 SECONDARY DATA
17.2.1.1 Key data from secondary sources
17.2.2 PRIMARY DATA
17.2.2.1 Key data from primary sources
17.2.2.2 Key industry insights
17.3 MARKET SIZE ESTIMATION
17.3.1 BOTTOM-UP APPROACH
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 MARKET SHARE ANALYSIS
17.5.1 RESEARCH ASSUMPTIONS
17.5.2 GROWTH RATE ASSUMPTIONS
17.6 RISK ASSESSMENT
17.7 RESEARCH LIMITATIONS
17.7.1 METHODOLOGY-RELATED LIMITATIONS
17.7.2 SCOPE-RELATED LIMITATIONS
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.3.1 PRODUCT ANALYSIS
18.3.2 COMPANY INFORMATION
18.3.3 GEOGRAPHIC ANALYSIS
18.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
18.3.5 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT
18.3.6 BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
18.3.7 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD)
TABLE 2 NUMBER OF US HOUSEHOLDS THAT OWN A PET IN 2025, BY ANIMAL TYPE (MILLIONS)
TABLE 3 AVERAGE PREMIUMS PAID IN US, 2023 VS. 2024
TABLE 4 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION)
TABLE 6 AVERAGE SELLING PRICE TREND OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF RAPID TEST KITS, BY REGION, 2023?2025
TABLE 8 AVERAGE SELLING PRICE TREND OF ELISA/IMMUNODIAGNOSTIC TEST KITS & REAGENTS, BY REGION, 2023?2025
TABLE 9 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES, BY REGION, 2023?2025
TABLE 10 AVERAGE SELLING PRICE TREND OF BLOOD GLUCOSE STRIPS, BY REGION, 2023?2025
TABLE 11 AVERAGE SELLING PRICE TREND OF HEMATOLOGY ANALYZERS, BY REGION, 2023?2025
TABLE 12 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 13 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 14 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 15 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 16 COMPANION ANIMAL DIAGNOSTICS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027
TABLE 17 CASE STUDY 1: NGS-BASED LIQUID BIOPSY FOR CANINE CANCER DETECTION
TABLE 18 CASE STUDY 2: ADOPTION OF AI -ENABLED POC DIAGNOSTIC PLATFORM FOR PARASITE DETECTION
TABLE 19 CASE STUDY 3: MULTIPLEX ELISA-BASED POC DIAGNOSTIC TEST: TARGETING VECTOR-BORNE DISEASE DETECTION
TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 21 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR COMPANION ANIMAL DIAGNOSTICS
TABLE 22 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
TABLE 23 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
TABLE 24 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
TABLE 25 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
TABLE 26 COMPANION ANIMAL DIAGNOSTICS MARKET: MAJOR PATENTS
TABLE 27 KEY COMPANIES IMPLEMENTING AI IN COMPANION ANIMAL DIAGNOSTICS MARKET
TABLE 28 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION ANIMAL DIAGNOSTICS PRODUCTS
TABLE 32 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 33 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 34 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC CONSUMABLES
TABLE 35 COMPANION ANIMAL DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 KEY PLAYERS PROVIDING COMPANION ANIMAL DIAGNOSTIC INSTRUMENTS
TABLE 37 COMPANION ANIMAL DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 39 KEY PLAYERS PROVIDING IMMUNODIAGNOSTIC TECHNOLOGIES
TABLE 40 COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 41 COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 KEY PLAYERS PROVIDING LATERAL FLOW ASSAYS
TABLE 43 LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 44 LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 KEY PLAYERS PROVIDING LATERAL FLOW RAPID TESTS
TABLE 46 RAPID TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 RAPID TESTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 48 KEY PLAYERS PROVIDING LATERAL FLOW STRIP READERS
TABLE 49 STRIP READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 STRIP READERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 51 KEY PLAYERS PROVIDING ELISA TESTS
TABLE 52 ELISA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 KEY PLAYERS PROVIDING ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS
TABLE 54 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 KEY PLAYERS PROVIDING IMMUNOASSAY ANALYZERS
TABLE 56 IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 KEY PLAYERS PROVIDING RADIOIMMUNOASSAYS
TABLE 58 RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 OTHER IMMUNODIAGNOSTICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 KEY PLAYERS PROVIDING CLINICAL BIOCHEMISTRY PRODUCTS
TABLE 61 COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 62 COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY ANALYSIS
TABLE 64 CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 65 CLINICAL CHEMISTRY ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES
TABLE 67 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 69 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY ANALYZERS
TABLE 70 CLINICAL CHEMISTRY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 72 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE ANALYSIS
TABLE 73 BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION)
TABLE 74 BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES
TABLE 76 BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 78 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE ANALYZERS
TABLE 79 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 81 KEY PLAYERS PROVIDING GLUCOSE MONITORING
TABLE 82 GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 83 GLUCOSE MONITORING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 KEY PLAYERS PROVIDING BLOOD GLUCOSE STRIPS
TABLE 85 BLOOD GLUCOSE STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 BLOOD GLUCOSE STRIPS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 87 KEY PLAYERS PROVIDING GLUCOSE MONITORS
TABLE 88 GLUCOSE MONITORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 GLUCOSE MONITORS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 90 KEY PLAYERS PROVIDING URINE GLUCOSE STRIPS
TABLE 91 URINE GLUCOSE STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 URINE GLUCOSE STRIPS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 93 KEY PLAYERS PROVIDING MOLECULAR DIAGNOSTICS
TABLE 94 COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 95 COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 KEY PLAYERS PROVIDING PCR TESTS
TABLE 97 PCR TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 MICROARRAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 NUCLEIC ACID SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 OTHER MOLECULAR DIAGNOSTICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 KEY PLAYERS PROVIDING URINALYSIS PRODUCTS
TABLE 102 COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 103 COMPANION ANIMAL URINALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 KEY PLAYERS PROVIDING URINALYSIS CLIPS & CARTRIDGES
TABLE 105 URINALYSIS CLIPS & CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 KEY PLAYERS PROVIDING URINE ANALYZERS
TABLE 107 URINE ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 KEY PLAYERS PROVIDING URINE TEST STRIPS
TABLE 109 URINE TEST STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 KEY PLAYERS PROVIDING HEMATOLOGY PRODUCTS
TABLE 111 COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 112 COMPANION ANIMAL HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 KEY PLAYERS PROVIDING HEMATOLOGY CARTRIDGES
TABLE 114 HEMATOLOGY CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 KEY PLAYERS PROVIDING HEMATOLOGY ANALYZERS
TABLE 116 HEMATOLOGY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 KEY PLAYERS PROVIDING OTHER TECHNOLOGIES
TABLE 118 OTHER COMPANION ANIMAL DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 120 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CLINICAL PATHOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 COMPANION ANIMAL DIAGNOSTICS MARKET FOR BACTERIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VIROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 COMPANION ANIMAL DIAGNOSTICS MARKET FOR PARASITOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 126 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR DOGS
TABLE 127 COMPANION ANIMAL DIAGNOSTICS MARKET FOR DOGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR CATS
TABLE 129 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CATS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR HORSES
TABLE 131 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HORSES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 134 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY RESEARCH INSTITUTES & UNIVERSITIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 139 COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS)
TABLE 141 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 143 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 144 NORTH AMERICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 145 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 146 NORTH AMERICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147 NORTH AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 148 NORTH AMERICA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 149 NORTH AMERICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150 NORTH AMERICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 NORTH AMERICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 153 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 154 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 155 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 156 US: KEY MACROINDICATORS
TABLE 157 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 158 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 159 US: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 US: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161 US: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 US: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 163 US: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 164 US: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165 US: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 166 US: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167 US: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 169 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 170 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 171 CANADA: KEY MACROINDICATORS
TABLE 172 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 173 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 174 CANADA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 175 CANADA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 176 CANADA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177 CANADA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 CANADA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 CANADA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 180 CANADA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 181 CANADA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 182 CANADA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 184 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 185 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS)
TABLE 187 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 189 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 190 EUROPE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 191 EUROPE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192 EUROPE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 194 EUROPE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 EUROPE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 EUROPE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197 EUROPE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198 EUROPE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 200 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 202 GERMANY: KEY MACROINDICATORS
TABLE 203 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 204 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 205 GERMANY: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206 GERMANY: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207 GERMANY: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208 GERMANY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209 GERMANY: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 210 GERMANY: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 211 GERMANY: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 GERMANY: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 GERMANY: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 215 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 216 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 217 UK: KEY MACROINDICATORS
TABLE 218 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 219 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 220 UK: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221 UK: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222 UK: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 223 UK: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 224 UK: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225 UK: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 UK: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227 UK: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 228 UK: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 230 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 231 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 232 FRANCE: KEY MACROINDICATORS
TABLE 233 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 234 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 235 FRANCE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 FRANCE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237 FRANCE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 FRANCE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239 FRANCE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 240 FRANCE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 241 FRANCE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242 FRANCE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 243 FRANCE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 244 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 245 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 246 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 247 ITALY: KEY MACROINDICATORS
TABLE 248 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 249 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 250 ITALY: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251 ITALY: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252 ITALY: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253 ITALY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254 ITALY: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255 ITALY: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 256 ITALY: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 257 ITALY: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 ITALY: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 259 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 260 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 261 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 262 SPAIN: KEY MACROINDICATORS
TABLE 263 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 264 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 265 SPAIN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266 SPAIN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 267 SPAIN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 268 SPAIN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269 SPAIN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270 SPAIN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 271 SPAIN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 272 SPAIN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273 SPAIN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 275 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 276 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 277 NETHERLANDS: KEY MACROINDICATORS
TABLE 278 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 279 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 280 NETHERLANDS: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 281 NETHERLANDS: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 282 NETHERLANDS: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 283 NETHERLANDS: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 284 NETHERLANDS: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 285 NETHERLANDS: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286 NETHERLANDS: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287 NETHERLANDS: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288 NETHERLANDS: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 290 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 291 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 292 SWEDEN: KEY MACROINDICATORS
TABLE 293 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 294 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 295 SWEDEN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296 SWEDEN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297 SWEDEN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298 SWEDEN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 299 SWEDEN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 300 SWEDEN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301 SWEDEN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302 SWEDEN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 303 SWEDEN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 304 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 305 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD)
TABLE 2 NUMBER OF US HOUSEHOLDS THAT OWN A PET IN 2025, BY ANIMAL TYPE (MILLIONS)
TABLE 3 AVERAGE PREMIUMS PAID IN US, 2023 VS. 2024
TABLE 4 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION)
TABLE 6 AVERAGE SELLING PRICE TREND OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF RAPID TEST KITS, BY REGION, 2023?2025
TABLE 8 AVERAGE SELLING PRICE TREND OF ELISA/IMMUNODIAGNOSTIC TEST KITS & REAGENTS, BY REGION, 2023?2025
TABLE 9 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES, BY REGION, 2023?2025
TABLE 10 AVERAGE SELLING PRICE TREND OF BLOOD GLUCOSE STRIPS, BY REGION, 2023?2025
TABLE 11 AVERAGE SELLING PRICE TREND OF HEMATOLOGY ANALYZERS, BY REGION, 2023?2025
TABLE 12 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 13 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 14 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 15 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 16 COMPANION ANIMAL DIAGNOSTICS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027
TABLE 17 CASE STUDY 1: NGS-BASED LIQUID BIOPSY FOR CANINE CANCER DETECTION
TABLE 18 CASE STUDY 2: ADOPTION OF AI -ENABLED POC DIAGNOSTIC PLATFORM FOR PARASITE DETECTION
TABLE 19 CASE STUDY 3: MULTIPLEX ELISA-BASED POC DIAGNOSTIC TEST: TARGETING VECTOR-BORNE DISEASE DETECTION
TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 21 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR COMPANION ANIMAL DIAGNOSTICS
TABLE 22 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
TABLE 23 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
TABLE 24 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
TABLE 25 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
TABLE 26 COMPANION ANIMAL DIAGNOSTICS MARKET: MAJOR PATENTS
TABLE 27 KEY COMPANIES IMPLEMENTING AI IN COMPANION ANIMAL DIAGNOSTICS MARKET
TABLE 28 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION ANIMAL DIAGNOSTICS PRODUCTS
TABLE 32 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 33 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 34 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC CONSUMABLES
TABLE 35 COMPANION ANIMAL DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 KEY PLAYERS PROVIDING COMPANION ANIMAL DIAGNOSTIC INSTRUMENTS
TABLE 37 COMPANION ANIMAL DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 39 KEY PLAYERS PROVIDING IMMUNODIAGNOSTIC TECHNOLOGIES
TABLE 40 COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 41 COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 KEY PLAYERS PROVIDING LATERAL FLOW ASSAYS
TABLE 43 LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 44 LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 KEY PLAYERS PROVIDING LATERAL FLOW RAPID TESTS
TABLE 46 RAPID TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 RAPID TESTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 48 KEY PLAYERS PROVIDING LATERAL FLOW STRIP READERS
TABLE 49 STRIP READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 STRIP READERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 51 KEY PLAYERS PROVIDING ELISA TESTS
TABLE 52 ELISA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 KEY PLAYERS PROVIDING ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS
TABLE 54 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 KEY PLAYERS PROVIDING IMMUNOASSAY ANALYZERS
TABLE 56 IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 KEY PLAYERS PROVIDING RADIOIMMUNOASSAYS
TABLE 58 RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 OTHER IMMUNODIAGNOSTICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 KEY PLAYERS PROVIDING CLINICAL BIOCHEMISTRY PRODUCTS
TABLE 61 COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 62 COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY ANALYSIS
TABLE 64 CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 65 CLINICAL CHEMISTRY ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES
TABLE 67 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 69 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY ANALYZERS
TABLE 70 CLINICAL CHEMISTRY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 72 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE ANALYSIS
TABLE 73 BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION)
TABLE 74 BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES
TABLE 76 BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 78 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE ANALYZERS
TABLE 79 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 81 KEY PLAYERS PROVIDING GLUCOSE MONITORING
TABLE 82 GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 83 GLUCOSE MONITORING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 KEY PLAYERS PROVIDING BLOOD GLUCOSE STRIPS
TABLE 85 BLOOD GLUCOSE STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 BLOOD GLUCOSE STRIPS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 87 KEY PLAYERS PROVIDING GLUCOSE MONITORS
TABLE 88 GLUCOSE MONITORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 GLUCOSE MONITORS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 90 KEY PLAYERS PROVIDING URINE GLUCOSE STRIPS
TABLE 91 URINE GLUCOSE STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 URINE GLUCOSE STRIPS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 93 KEY PLAYERS PROVIDING MOLECULAR DIAGNOSTICS
TABLE 94 COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 95 COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 KEY PLAYERS PROVIDING PCR TESTS
TABLE 97 PCR TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 MICROARRAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 NUCLEIC ACID SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 OTHER MOLECULAR DIAGNOSTICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 KEY PLAYERS PROVIDING URINALYSIS PRODUCTS
TABLE 102 COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 103 COMPANION ANIMAL URINALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 KEY PLAYERS PROVIDING URINALYSIS CLIPS & CARTRIDGES
TABLE 105 URINALYSIS CLIPS & CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 KEY PLAYERS PROVIDING URINE ANALYZERS
TABLE 107 URINE ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 KEY PLAYERS PROVIDING URINE TEST STRIPS
TABLE 109 URINE TEST STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 KEY PLAYERS PROVIDING HEMATOLOGY PRODUCTS
TABLE 111 COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 112 COMPANION ANIMAL HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 KEY PLAYERS PROVIDING HEMATOLOGY CARTRIDGES
TABLE 114 HEMATOLOGY CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 KEY PLAYERS PROVIDING HEMATOLOGY ANALYZERS
TABLE 116 HEMATOLOGY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 KEY PLAYERS PROVIDING OTHER TECHNOLOGIES
TABLE 118 OTHER COMPANION ANIMAL DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 120 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CLINICAL PATHOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 COMPANION ANIMAL DIAGNOSTICS MARKET FOR BACTERIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VIROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 COMPANION ANIMAL DIAGNOSTICS MARKET FOR PARASITOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 126 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR DOGS
TABLE 127 COMPANION ANIMAL DIAGNOSTICS MARKET FOR DOGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR CATS
TABLE 129 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CATS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR HORSES
TABLE 131 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HORSES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 134 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY RESEARCH INSTITUTES & UNIVERSITIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 139 COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS)
TABLE 141 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 143 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 144 NORTH AMERICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 145 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 146 NORTH AMERICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147 NORTH AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 148 NORTH AMERICA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 149 NORTH AMERICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150 NORTH AMERICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 NORTH AMERICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 153 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 154 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 155 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 156 US: KEY MACROINDICATORS
TABLE 157 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 158 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 159 US: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 US: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161 US: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 US: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 163 US: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 164 US: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165 US: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 166 US: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167 US: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 169 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 170 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 171 CANADA: KEY MACROINDICATORS
TABLE 172 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 173 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 174 CANADA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 175 CANADA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 176 CANADA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177 CANADA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 CANADA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 CANADA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 180 CANADA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 181 CANADA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 182 CANADA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 184 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 185 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS)
TABLE 187 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 189 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 190 EUROPE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 191 EUROPE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192 EUROPE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 194 EUROPE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 EUROPE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 EUROPE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197 EUROPE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198 EUROPE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 200 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 202 GERMANY: KEY MACROINDICATORS
TABLE 203 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 204 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 205 GERMANY: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206 GERMANY: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207 GERMANY: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208 GERMANY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209 GERMANY: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 210 GERMANY: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 211 GERMANY: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 GERMANY: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 GERMANY: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 215 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 216 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 217 UK: KEY MACROINDICATORS
TABLE 218 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 219 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 220 UK: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221 UK: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222 UK: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 223 UK: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 224 UK: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225 UK: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 UK: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227 UK: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 228 UK: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 230 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 231 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 232 FRANCE: KEY MACROINDICATORS
TABLE 233 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 234 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 235 FRANCE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 FRANCE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237 FRANCE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 FRANCE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239 FRANCE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 240 FRANCE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 241 FRANCE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242 FRANCE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 243 FRANCE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 244 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 245 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 246 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 247 ITALY: KEY MACROINDICATORS
TABLE 248 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 249 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 250 ITALY: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251 ITALY: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252 ITALY: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253 ITALY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254 ITALY: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255 ITALY: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 256 ITALY: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 257 ITALY: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 ITALY: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 259 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 260 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 261 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 262 SPAIN: KEY MACROINDICATORS
TABLE 263 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 264 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 265 SPAIN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266 SPAIN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 267 SPAIN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 268 SPAIN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269 SPAIN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270 SPAIN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 271 SPAIN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 272 SPAIN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273 SPAIN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 275 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 276 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 277 NETHERLANDS: KEY MACROINDICATORS
TABLE 278 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 279 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 280 NETHERLANDS: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 281 NETHERLANDS: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 282 NETHERLANDS: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 283 NETHERLANDS: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 284 NETHERLANDS: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 285 NETHERLANDS: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286 NETHERLANDS: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287 NETHERLANDS: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288 NETHERLANDS: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 290 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 291 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 292 SWEDEN: KEY MACROINDICATORS
TABLE 293 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 294 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 295 SWEDEN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296 SWEDEN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297 SWEDEN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298 SWEDEN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 299 SWEDEN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 300 SWEDEN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301 SWEDEN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302 SWEDEN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 303 SWEDEN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 304 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 305 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 COMPANION ANIMAL DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL COMPANION ANIMAL DIAGNOSTICS MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2022–2025
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF COMPANION ANIMAL DIAGNOSTICS MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN COMPANION ANIMAL DIAGNOSTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 RISING COMPANION ANIMAL POPULATION TO FUEL MARKET GROWTH
FIGURE 9 CONSUMABLES SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 10 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 13 COMPANION ANIMAL DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 US: PET EXPENDITURE, DOGS VS CATS, 2024 (USD)
FIGURE 15 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 16 COMPANION ANIMAL DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 COMPANION ANIMAL DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2025 (USD)
FIGURE 19 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY REGION, 2025
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 21 COMPANION ANIMAL DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO (2021–2025)
FIGURE 22 COMPANION ANIMAL DIAGNOSTIC MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2015–MAY 2026)
FIGURE 23 TOP APPLICANT COUNTRIES/REGIONS FOR COMPANION ANIMAL DIAGNOSTIC KITS PATENTS (JANUARY 2015–MAY 2026)
FIGURE 24 AI USE CASES
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR COMPANION ANIMAL DIAGNOSTIC PRODUCTS
FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 27 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT
FIGURE 28 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN THE COMPANION ANIMAL DIAGNOSTICS MARKET (2021?2025)
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS (2025)
FIGURE 32 RANKING OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2025
FIGURE 33 US: MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 34 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 35 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 36 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 37 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 38 COMPANION ANIMAL DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 39 R&D EXPENDITURE OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2022?2025
FIGURE 40 EV/EBITDA OF KEY VENDORS
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 42 IDEXX LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 43 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2025)
FIGURE 44 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 46 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 47 VIRBAC: COMPANY SNAPSHOT (2025)
FIGURE 48 BOULE: COMPANY SNAPSHOT (2025)
FIGURE 49 COMPANION ANIMAL DIAGNOSTICS MARKET: RESEARCH DESIGN
FIGURE 50 PRIMARY SOURCES
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE)
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE)
FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 54 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 55 REVENUE SHARE ANALYSIS ILLUSTRATION: IDEXX LABORATORIES, INC.
FIGURE 56 REVENUE ANALYSIS OF TOP FIVE COMPANIES: COMPANION ANIMAL DIAGNOSTICS MARKET (2025)
FIGURE 57 DEMAND-SIDE MARKET ESTIMATION FOR COMPANION ANIMAL DIAGNOSTICS MARKET
FIGURE 58 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF COMPANION ANIMAL DIAGNOSTICS MARKET (2026–2031)
FIGURE 59 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 60 TOP-DOWN APPROACH
FIGURE 61 BOTTOM-UP APPROACH
FIGURE 62 MARKET DATA TRIANGULATION METHODOLOGY
FIGURE 1 COMPANION ANIMAL DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL COMPANION ANIMAL DIAGNOSTICS MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2022–2025
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF COMPANION ANIMAL DIAGNOSTICS MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN COMPANION ANIMAL DIAGNOSTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 RISING COMPANION ANIMAL POPULATION TO FUEL MARKET GROWTH
FIGURE 9 CONSUMABLES SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 10 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 13 COMPANION ANIMAL DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 US: PET EXPENDITURE, DOGS VS CATS, 2024 (USD)
FIGURE 15 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 16 COMPANION ANIMAL DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 COMPANION ANIMAL DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2025 (USD)
FIGURE 19 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY REGION, 2025
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 21 COMPANION ANIMAL DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO (2021–2025)
FIGURE 22 COMPANION ANIMAL DIAGNOSTIC MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2015–MAY 2026)
FIGURE 23 TOP APPLICANT COUNTRIES/REGIONS FOR COMPANION ANIMAL DIAGNOSTIC KITS PATENTS (JANUARY 2015–MAY 2026)
FIGURE 24 AI USE CASES
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR COMPANION ANIMAL DIAGNOSTIC PRODUCTS
FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 27 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT
FIGURE 28 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN THE COMPANION ANIMAL DIAGNOSTICS MARKET (2021?2025)
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS (2025)
FIGURE 32 RANKING OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2025
FIGURE 33 US: MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 34 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 35 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 36 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 37 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 38 COMPANION ANIMAL DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 39 R&D EXPENDITURE OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2022?2025
FIGURE 40 EV/EBITDA OF KEY VENDORS
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 42 IDEXX LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 43 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2025)
FIGURE 44 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 46 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 47 VIRBAC: COMPANY SNAPSHOT (2025)
FIGURE 48 BOULE: COMPANY SNAPSHOT (2025)
FIGURE 49 COMPANION ANIMAL DIAGNOSTICS MARKET: RESEARCH DESIGN
FIGURE 50 PRIMARY SOURCES
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE)
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE)
FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 54 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 55 REVENUE SHARE ANALYSIS ILLUSTRATION: IDEXX LABORATORIES, INC.
FIGURE 56 REVENUE ANALYSIS OF TOP FIVE COMPANIES: COMPANION ANIMAL DIAGNOSTICS MARKET (2025)
FIGURE 57 DEMAND-SIDE MARKET ESTIMATION FOR COMPANION ANIMAL DIAGNOSTICS MARKET
FIGURE 58 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF COMPANION ANIMAL DIAGNOSTICS MARKET (2026–2031)
FIGURE 59 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 60 TOP-DOWN APPROACH
FIGURE 61 BOTTOM-UP APPROACH
FIGURE 62 MARKET DATA TRIANGULATION METHODOLOGY
